-
AALI SHER 2 months ago
VIVALIS further diversifies via its proprietary drug‑discovery platform — the 3D‑Screen™ platform — used for early-stage discovery of small molecules that can modulate protein conformation, a potentially powerful approach for new therapeutics. Among its targets, VIVALIS has reportedly worked on antiviral molecules — including ones for hepatitis‑C — though as with many preclinical ventures, success and regulatory approval are subject to many uncertainties.